Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Events

Rabies Vaccine Supply Situation

Current Situation

As a result of collaborative efforts with public health and government officials, Novartis has additional supplies of rabies vaccine for distribution. The company has announced that effective October 7, 2008, they are able to deliver RabAvert vaccine for post-exposure prophylaxis, without supply restrictions.

The Novartis product identification number has changed from 53905-501-01 to 63851-501-01.

Questions can be directed to Novartis customer service at 1-800-244-7668.

Sanofi Pasteur continues to have IMOVAX vaccine available for post-exposure prophylaxis.

To obtain IMOVAX rabies vaccine you must first contact your Rabies State Health Official so that a risk-assessment can be conducted for the suspected exposure. If your Rabies State Health Official determines that rabies post-exposure prophylaxis is indicated they will provide you with a passcode to place on the Sanofi Pasteur Rabies Post-Exposure Form. The form must be filled out in its entirety, including the required physician’s signature and passcode provided by your Rabies State Health Official. Please contact Sanofi Pasteur at 1-800-VACCINE to obtain the required form. Please click here for a list of the Rabies State Health Officials.

Why is there an interruption in supply?

Starting in June 2007, Sanofi Pasteur began renovating its IMOVAX Rabies vaccine production facility in France to maintain compliance with the most current requirements from FDA and the French regulatory body. Prior to these renovations, Sanofi Pasteur established an inventory based on historical levels of sales and projected market demand. The facility is scheduled to be approved and operational by mid-to-late 2009. Until the facility is operational, Sanofi Pasteur has a finite amount of IMOVAX Rabies vaccine.

After the renovations began, Novartis, the other supplier of rabies vaccine for the United States, was unable to meet projected rabies vaccine supplies.

Since early 2008, Novartis has been supplying its rabies vaccine, RabAvert, for post-exposure use only. Consequently, Sanofi Pasteur has been supplying nearly all of the market for rabies vaccine. The increase in demand for IMOVAX is outpacing the company s historical levels of supply.

How does this affect current rabies vaccination recommendations?

Persons at increased risk for rabies exposure should take appropriate precautions to avoid rabies exposure

Vaccine is available for PEP, and providers should consult with their local or state public health department to ensure appropriate use of PEP